Balogh, Erin
QRcode
자료유형 | E-BOOK |
---|---|
서명/저자사항 | Advancing progress in the development of combination cancer therapies with immune checkpoint inhibitors : proceedings of a workshop/ Erin Balogh and Sharyl J. Nass, Rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, the National Academies of Sciences, Engineering, Medicine. |
개인저자 | Balogh, Erin,rapporteur. Nass, Sharyl J.,rapporteur, |
단체저자명 | National Cancer Policy Forum (U.S.),issuing body. |
발행사항 | Washington, DC: the National Academies Press, [2019]. |
형태사항 | 1 online resource (xiiii, 65 pages): color illustrations. |
기타형태 저록 | Print version: National Academies of Sciences, Engineering, and Medicine. Advancing progress in the development of combination cancer therapies with immune checkpoint inhibitors. Washington, DC: National Academies Press, 2019. 0309490863 |
ISBN | 9780309490870 0309490871 9780309490894 0309490898 |
서지주기 | Includes bibliographical references. |
요약 | "In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have proteins that regulate the immune system response to foreign invaders (e.g., cancer cells, microorganisms). However, cancer cells can coopt these "checkpoint" proteins and thwart the immune system's ability to recognize and attack cancer cells. To help promote an immune response to cancer, researchers have developed immune checkpoint inhibitors that enable T-cells to recognize cancer cells as foreign and to prevent deactivation of an immune system response. To examine the challenges and opportunities to develop combination cancer therapies that include immune checkpoint inhibitors, the National Cancer Policy Forum held a workshop on July 16-17, 2018, in Washington, DC. This workshop convened stakeholders with a broad range of expertise, including cancer researchers, clinicians, patient advocates, and representatives from industry, academia, and government. This publication summarizes the presentations and discussions from the workshop"--Publisher's description |
회의명 | Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors (Workshop) (2018 : Washington, D.C.), |
일반주제명 | Chemotherapy, Combination --Congresses. Cancer --Treatment --Congresses. Cancer --Immunotherapy --Congresses. Cancer --Chemotherapy --Congresses. Cancer --Immunological aspects. |
언어 | 영어 |
바로가기 | URL |
서평 (0 건)
*주제와 무관한 내용의 서평은 삭제될 수 있습니다.
서평추가